Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPI-547 in Advanced Solid Tumors
NCT04335604Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nesuparib in solid tumor (advanced stage), sponsored by Onconic Therapeutics Inc. Primary endpoints: Dose-limiting toxicity at 21 days and Maximum tolerated dose at 21 days. Started Dec 2017; status: completed.
02
Drugs
nesuparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04335604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335604.